Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
Patients With Rheumatic Diseases at No Greater Risk of Contracting COVID-19
November 4th 2020Despite concerns about treatment with immunosuppressive agents, coronavirus disease 2019 (COVID-19) infection remains low in patients with rheumatic diseases, according to 2 abstracts presented at the annual meeting of the American College of Rheumatology.
Read More
PROs: Which Are Important to Patients and How Successfully Are They Integrated Into Clinical Care?
November 14th 2019Although patient-reported outcomes (PROs) are increasingly being used to understand treatment effectiveness, there is still a lot unknown about what measures patients find most important. Two abstracts presented at the American College of Rheumatology’s annual meeting evaluated PROs in rheumatology and how PRO measures can be used in clinical care.
Read More
Treating Pain in Rheumatologic Diseases With Opioids
November 14th 2019Pain is common in patients with rheumatologic diseases, and 2 abstracts presented at the American College of Rheumatology’s annual meeting analyzed opioid use in these patients, examining patient features associated with chronic use and changing opioid use patterns in the wake of the opioid epidemic.
Read More
The Many Benefits of, and Barriers to, Exercise in Patients With Rheumatologic Diseases
November 14th 2019Exercise can be a potent therapy for patients with rheumatologic diseases and can result in improvements in inflammation, disease activity score, pain, stiffness, and fatigue. However, exercise needs to be modified for these patients to address the unique barriers they may have compared with the general population, said panelists during a session at the American College of Rheumatology’s annual meeting.
Read More
Patients with rheumatoid arthritis (RA) not only deal with functional impairment, but also pain, fatigue, and other symptoms driven by interleukin (IL)-6 levels. In a session at the American College of Rheumatology’s annual meeting, 2 speakers examined the role of IL-6 in RA and treatment using sarilumab (Kevzara) to target and block IL-6 signals.
Read More
Using Technology and Virtual Reality to Improve Outcomes, Quality of Life
November 13th 2019New technologies that can monitor sleep, track itching patterns, or assist with pain are improving outcomes and quality of life for patients with rheumatologic conditions, according to panelists at the American College of Rheumatology’s annual meeting.
Read More
Evaluating Sarilumab's Efficacy as a Monotherapy in Rheumatoid Arthritis
November 13th 2019Monotherapy was a big topic of conversation at the American College of Rheumatology’s annual meeting, held November 8-13 in Atlanta, Georgia, and 2 abstracts highlight the efficacy of sarilumab as a monotherapy in patients with rheumatoid arthritis.
Read More
Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA
November 13th 2019Since there are no cures for knee osteoarthritis (OA), exercise and weight loss remain the best first-line therapies to decrease pain and improve function, said Stephen P. Messier, PhD, professor and director of the J.B. Snow Biomechanics Laboratory at Wake Forest University.
Read More
Patients with rheumatoid arthritis receiving sarilumab have lower odds of unacceptable pain and are able to reduce their dose of oral glucocorticoid; they also have lower costs per responder than most other treatments, according to a trio of abstracts presented at the American College of Rheumatology/Association of Rheumatology Professionals 2019 Annual Meeting.
Read More
How Prior Authorization, Step Therapy Result in Medication Discontinuation and Worse Outcomes
November 12th 2019Utilization management tools, such as step therapy and prior authorization, are not only time consuming for patients, but they are a burden on providers and their practices due to the time and effort spent on the process, explained Jessica Farrell, PharmD, and Madelaine Feldman, MD, FACR, during their session at 2019 ACR/ARP Annual Meeting, held November 8-13 in Atlanta, Georgia.
Read More
Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested
November 12th 2019While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.
Read More
Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients
November 11th 2019Patients with immunosuppressive conditions, particularly those being treated with tumor necrosis factor inhibitors, are vulnerable to infections, but rheumatologists have mostly been hesitant to use any live virus vaccines in these patients, said Jeffrey R. Curtis, MD, MS, MPH, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
Read More
Using Patient Characteristics to Predict Clinical Outcomes in RA
November 11th 2019Grouping patients into clusters based on shared characteristics, such as disease control and general health, may be helpful in understanding and predicting clinical outcomes in patients with rheumatoid arthritis (RA), according to an abstract presented at the 2019 ACR/ARP Annual Meeting, held November 8-13 in Atlanta, Georgia.
Read More
Dr Daniel Clauw Highlights the Turn Toward Nondrug Therapies to Treat Chronic Pain
November 11th 2019Nondrug therapies that might have been dismissed 30 years ago are now the sorts of treatments physicians are turning to instead of overused treatments like surgical procedures, opioids, and injections, said Daniel Clauw, MD, professor of anesthesiology, medicine (rheumatology), and psychiatry; director of translational research; and director of the Center for Chronic Pain and Fatigue Research.
Read More
Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis
November 11th 2019Disease activity assessments can help physicians treat to targets, but in some areas those targets have not been set yet, said Yusuf Yazici, MD, clinical associate professor in the Department of Medicine at NYU Langone Health.
Read More
2019 Brought Impressive Results for TNF Inhibitors, Research Into Monotherapy, Interest in CBD
November 10th 2019This year has been an exciting time for rheumatologists with impressive clinical trial results and promising outcomes for patients, said Susan Manzi, MD, MPH, codirector of the Lupus Center of Excellence and chair of the Department of Medicine of West Penn Allegheny Health System, during a session at the American College of Rheumatology annual meeting in Atlanta, Georgia.
Read More
Federal Agencies Address the Dual Crises of Pain and Opioid Addiction
November 8th 2017In a Tuesday panel discussion at The American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, representatives from HHS, the National Institutes of Health (NIH), and the CDC outlined ongoing federal initiatives to address the parallel problems of pain and opioid addiction.
Read More
ACR and NPF Unveil New Clinical Guideline for Treating Psoriatic Arthritis
November 8th 2017On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.
Read More
Value-Based Contracting in the "Era of Unknowns"
November 8th 2017In a Tuesday session at the American College of Rheumatology’s 2017 Annual Meeting in San Diego, California, Greg Mertz, MBA, FACMPE, managing director for Physician Strategies Group, LLC, presented a talk title “Value Contracting: Opportunities of Fantasy?” in which he outlined the current landscape for performance-based contracting.
Read More
Abstracts Analyze Collected EHR Data and Sarilumab Outcomes for Patients With RA
November 7th 2017A recap of abstracts presented at The American College of Rheumatology’s 2017 Annual Meeting, including an analysis of data available in an electronic health records database and outcomes and cost effectiveness of sarilumab.
Read More
2017 Sees Progress in Approvals for Anti-Rheumatic Drugs
November 7th 2017Kamala Nola, PharmD, MS, professor at the Lipscomb University College of Pharmacy, provided an overview of the drugs that have been approved in the past year for the treatment of inflammatory conditions during a session at the 2017 American College of Rheumatology Annual Meeting,
Read More
Rheumatology Patients at Increased Risk for Cardiac Disease
November 7th 2017During a session at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, a cardiologist joined rheumatologists to give a detailed look at the relationship between rheumatic conditions and cardiovascular disease.
Read More
MACRA Challenges Lead to New ACR Alternative Payment Model
November 6th 2017A panel discussion, titled, "Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS and APMs," was presented on Sunday at the 2017 American College of Rheumatology (ACR) Annual Meeting in San Diego, California.
Read More
Rheumatologists' Frustrations With PBMs Take Center Stage
November 6th 2017The title "Reshaping the Relationship Between Physicians and PBMs" suggested that the Sunday session at the 2017 American College of Rheumatology’s Annual Meeting in San Diego, California, would focus on reconciling the goals of providers and pharmacy benefit managers (PBMs), but physicians’ challenges in dealing with PBMs quickly became the primary focus of the panel discussion.
Read More
Dr Grace C. Wright Explains How Vectra DA Helps Choose Treatments in RA
December 28th 2016Treating patients with rheumatoid arthritis can be difficult because the available drugs do not treat all symptoms. However, the Vectra DA test can help physicians more quickly understand if a patient is responding or needs to switch therapies, explained Grace C. Wright, MD, PhD, clinical associate professor of medicine and attending rheumatologist at New York University Langone Medical Center.
Read More
Dr Allan Gibofsky: The Need for Individualized Treatments in RA
December 21st 2016There is a need in rheumatoid arthritis to be able to individualize treatments, but without credible and reliable biomarkers, it just isn't possible yet, said Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.
Read More